SE524990C2 - Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver - Google Patents
Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulverInfo
- Publication number
- SE524990C2 SE524990C2 SE0201125A SE0201125A SE524990C2 SE 524990 C2 SE524990 C2 SE 524990C2 SE 0201125 A SE0201125 A SE 0201125A SE 0201125 A SE0201125 A SE 0201125A SE 524990 C2 SE524990 C2 SE 524990C2
- Authority
- SE
- Sweden
- Prior art keywords
- dry powder
- dose
- powder
- powder preparation
- therapeutic
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract description 211
- 238000000034 method Methods 0.000 title claims abstract description 84
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 238000003892 spreading Methods 0.000 title description 2
- 230000007480 spreading Effects 0.000 title description 2
- 239000002245 particle Substances 0.000 claims abstract description 121
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 88
- 239000000758 substrate Substances 0.000 claims description 64
- 102000004877 Insulin Human genes 0.000 claims description 44
- 108090001061 Insulin Proteins 0.000 claims description 44
- 229940125396 insulin Drugs 0.000 claims description 44
- 238000009826 distribution Methods 0.000 claims description 35
- 239000013543 active substance Substances 0.000 claims description 24
- 210000004072 lung Anatomy 0.000 claims description 23
- 238000012384 transportation and delivery Methods 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 238000000151 deposition Methods 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 239000010419 fine particle Substances 0.000 claims description 7
- 230000000144 pharmacologic effect Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 238000000638 solvent extraction Methods 0.000 claims description 7
- 230000005520 electrodynamics Effects 0.000 claims description 6
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 5
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 5
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 5
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 5
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 5
- 229940047124 interferons Drugs 0.000 claims description 5
- 229960001319 parathyroid hormone Drugs 0.000 claims description 5
- 239000000199 parathyroid hormone Substances 0.000 claims description 5
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 102000001690 Factor VIII Human genes 0.000 claims description 4
- 108010054218 Factor VIII Proteins 0.000 claims description 4
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 4
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 4
- 239000000854 Human Growth Hormone Substances 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 229940047120 colony stimulating factors Drugs 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 229940112141 dry powder inhaler Drugs 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- 229960000301 factor viii Drugs 0.000 claims description 4
- 229940063135 genotropin Drugs 0.000 claims description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 3
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 3
- 238000007493 shaping process Methods 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 238000012938 design process Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 31
- 229940079593 drug Drugs 0.000 abstract description 30
- 230000033001 locomotion Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 5
- 238000004220 aggregation Methods 0.000 abstract 2
- 239000011164 primary particle Substances 0.000 description 13
- 238000005520 cutting process Methods 0.000 description 12
- 230000008021 deposition Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000006073 displacement reaction Methods 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000010422 painting Methods 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 5
- 238000012385 systemic delivery Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000003973 paint Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 3
- 241000220317 Rosa Species 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- 239000012907 medicinal substance Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- -1 Buprenorene Chemical compound 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002664 inhalation therapy Methods 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005276 aerator Methods 0.000 description 1
- 238000001856 aerosol method Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 229960003029 ketobemidone Drugs 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0048—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged in a plane, e.g. on diskettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/005—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a cylindrical surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/02—Inhalators with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201125A SE524990C2 (sv) | 2002-04-12 | 2002-04-12 | Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver |
| US10/134,597 US6881398B2 (en) | 2002-04-12 | 2002-04-30 | Therapeutic dry powder preparation |
| RU2004132859/14A RU2333014C2 (ru) | 2002-04-12 | 2003-04-04 | Ингалятор сухого порошка |
| CA002482263A CA2482263A1 (en) | 2002-04-12 | 2003-04-04 | Therapeutic dry powder preparation |
| JP2003583526A JP2005522494A (ja) | 2002-04-12 | 2003-04-04 | 治療用乾燥粉末調製物 |
| PCT/SE2003/000540 WO2003086516A1 (en) | 2002-04-12 | 2003-04-04 | Therapeutic dry powder preparation |
| ZA200408941A ZA200408941B (en) | 2002-04-12 | 2003-04-04 | Therapeutic dry powder preparation |
| BR0309174-0A BR0309174A (pt) | 2002-04-12 | 2003-04-04 | Preparação terapêutica na forma de pó seco |
| MXPA04010003A MXPA04010003A (es) | 2002-04-12 | 2003-04-04 | Preparacion terapeutica en polvo anhidro. |
| EP03717839A EP1496967A1 (en) | 2002-04-12 | 2003-04-04 | Therapeutic dry powder preparation |
| KR10-2004-7016353A KR20040097351A (ko) | 2002-04-12 | 2003-04-04 | 치료학적 건조 분말 제제 |
| AU2003222538A AU2003222538B2 (en) | 2002-04-12 | 2003-04-04 | Therapeutic dry powder preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201125A SE524990C2 (sv) | 2002-04-12 | 2002-04-12 | Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE0201125D0 SE0201125D0 (sv) | 2002-04-12 |
| SE0201125L SE0201125L (sv) | 2003-10-13 |
| SE524990C2 true SE524990C2 (sv) | 2004-11-09 |
Family
ID=20287575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0201125A SE524990C2 (sv) | 2002-04-12 | 2002-04-12 | Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6881398B2 (ja) |
| EP (1) | EP1496967A1 (ja) |
| JP (1) | JP2005522494A (ja) |
| KR (1) | KR20040097351A (ja) |
| AU (1) | AU2003222538B2 (ja) |
| BR (1) | BR0309174A (ja) |
| CA (1) | CA2482263A1 (ja) |
| MX (1) | MXPA04010003A (ja) |
| RU (1) | RU2333014C2 (ja) |
| SE (1) | SE524990C2 (ja) |
| WO (1) | WO2003086516A1 (ja) |
| ZA (1) | ZA200408941B (ja) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030235538A1 (en) * | 2002-04-09 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for the administration of an anticholinergic by inhalation |
| SE524957C2 (sv) * | 2002-04-12 | 2004-11-02 | Microdrug Ag | Förfarande för uppdelning och fördelning i luft av torrt pulvermedikament |
| SE0303269L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medicinsk produkt |
| SE0303270L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
| AU2004294889B2 (en) * | 2003-12-03 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Medical product containing tiotropium |
| SE0303571D0 (sv) * | 2003-12-03 | 2003-12-22 | Microdrug Ag | Medical product for moisture-sensitive medicaments |
| SE0303570L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
| SE0303569L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | DPI för avlämning av fuktkänsliga medikament |
| NZ549589A (en) * | 2004-02-24 | 2009-10-30 | Microdose Therapeutx Inc | Synthetic jet based medicament delivery method and apparatus |
| SE528121C2 (sv) * | 2004-03-29 | 2006-09-05 | Mederio Ag | Preparering av torrpulver för på förhand uppmätt DPI |
| SE530006C2 (sv) * | 2004-06-18 | 2008-02-05 | Mederio Ag | Inhalator som använder balja |
| SE0402345L (sv) * | 2004-09-24 | 2006-03-25 | Mederio Ag | Uppmätt läkemedelsdos |
| SE0402976L (sv) * | 2004-12-03 | 2006-06-04 | Mederio Ag | Medicinsk produkt |
| TWI274641B (en) * | 2005-08-30 | 2007-03-01 | Rexon Ind Corp Ltd | Cutting machine |
| US20070101991A1 (en) * | 2005-11-08 | 2007-05-10 | Mederio Ag | Optimizing release of dry medicament powder |
| GB0616299D0 (en) * | 2006-08-16 | 2006-09-27 | Cambridge Consultants | Drug Capsules for dry power inhalers |
| JP2010508069A (ja) | 2006-10-25 | 2010-03-18 | ノバルティス アーゲー | パウダー分散装置、その装置の製造方法および使用方法、その装置および他の装置に使用される構成要素 |
| US8196576B2 (en) * | 2007-02-28 | 2012-06-12 | Microdose Therapeutx, Inc. | Inhaler |
| WO2009055742A2 (en) * | 2007-10-24 | 2009-04-30 | Mannkind Corporation | Delivery of active agents |
| CA2709071C (en) | 2007-12-14 | 2016-11-15 | Labogroup S.A.S. | Delivering aerosolizable food products |
| RU2457855C2 (ru) * | 2008-08-05 | 2012-08-10 | Виктор Владимирович Чалов | Противовирусная и антимикробная композиция |
| US8985101B2 (en) | 2009-05-21 | 2015-03-24 | Microdose Therapeutx, Inc. | Method and device for clamping a blister within a dry powder inhaler |
| EP2432536B1 (en) * | 2009-05-21 | 2018-07-04 | MicroDose Therapeutx, Inc. | Rotary cassette system for dry powder inhaler |
| US9180263B2 (en) * | 2009-07-01 | 2015-11-10 | Microdose Therapeutx, Inc. | Laboratory animal pulmonary dosing device |
| US20110000481A1 (en) * | 2009-07-01 | 2011-01-06 | Anand Gumaste | Nebulizer for infants and respiratory compromised patients |
| EP3431128A1 (en) | 2010-01-05 | 2019-01-23 | MicroDose Therapeutx, Inc. | Inhalation device and method |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| ES2920802T3 (es) * | 2013-03-26 | 2022-08-09 | Optinose As | Administración nasal |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| WO2014178891A1 (en) | 2013-04-30 | 2014-11-06 | Otitopic Inc. | Dry powder formulations and methods of use |
| EP4119131A1 (en) | 2014-02-20 | 2023-01-18 | Otitopic Inc. | Dry powder formulations for inhalation |
| US10610651B2 (en) * | 2014-06-09 | 2020-04-07 | Aerami Therapeutics, Inc. | Self-puncturing liquid drug cartridges and associated dispenser |
| GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| GB2542838B (en) * | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| WO2018071427A1 (en) | 2016-10-11 | 2018-04-19 | Microdose Therapeutx, Inc. | Inhaler and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU643435B2 (en) | 1989-04-28 | 1993-11-18 | Riker Laboratories, Inc. | Dry powder inhalation device |
| GB9024760D0 (en) | 1990-11-14 | 1991-01-02 | Riker Laboratories Inc | Inhalation device and medicament carrier |
| US5469843A (en) | 1991-11-12 | 1995-11-28 | Minnesota Mining And Manufacturing Company | Inhalation device |
| US5441060A (en) * | 1993-02-08 | 1995-08-15 | Duke University | Dry powder delivery system |
| US5388573A (en) * | 1993-12-02 | 1995-02-14 | Tenax Corporation | Dry powder inhalator medicament carrier |
| US5503869A (en) * | 1994-10-21 | 1996-04-02 | Glaxo Wellcome Inc. | Process for forming medicament carrier for dry powder inhalator |
| US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US5714007A (en) | 1995-06-06 | 1998-02-03 | David Sarnoff Research Center, Inc. | Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate |
| SE504458C2 (sv) | 1995-06-21 | 1997-02-17 | Lars Gunnar Nilsson | Inhalator för elektrisk dosering av substanser |
| US5857456A (en) | 1996-06-10 | 1999-01-12 | Sarnoff Corporation | Inhaler apparatus with an electronic means for enhanced release of dry powders |
| SE517806C2 (sv) * | 1999-11-11 | 2002-07-16 | Microdrug Ag | Doseringsanordning för inhalator |
| SE516555C2 (sv) | 2000-08-04 | 2002-01-29 | Microdrug Ag | Elektropulver |
| SE516554C2 (sv) | 2000-08-31 | 2002-01-29 | Microdrug Ag | Uppmätt elektrodos |
| SE524957C2 (sv) * | 2002-04-12 | 2004-11-02 | Microdrug Ag | Förfarande för uppdelning och fördelning i luft av torrt pulvermedikament |
-
2002
- 2002-04-12 SE SE0201125A patent/SE524990C2/sv not_active IP Right Cessation
- 2002-04-30 US US10/134,597 patent/US6881398B2/en not_active Expired - Fee Related
-
2003
- 2003-04-04 EP EP03717839A patent/EP1496967A1/en not_active Withdrawn
- 2003-04-04 AU AU2003222538A patent/AU2003222538B2/en not_active Ceased
- 2003-04-04 BR BR0309174-0A patent/BR0309174A/pt not_active IP Right Cessation
- 2003-04-04 RU RU2004132859/14A patent/RU2333014C2/ru not_active IP Right Cessation
- 2003-04-04 KR KR10-2004-7016353A patent/KR20040097351A/ko not_active Application Discontinuation
- 2003-04-04 WO PCT/SE2003/000540 patent/WO2003086516A1/en active IP Right Grant
- 2003-04-04 MX MXPA04010003A patent/MXPA04010003A/es unknown
- 2003-04-04 JP JP2003583526A patent/JP2005522494A/ja not_active Withdrawn
- 2003-04-04 ZA ZA200408941A patent/ZA200408941B/en unknown
- 2003-04-04 CA CA002482263A patent/CA2482263A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003222538B2 (en) | 2007-05-03 |
| ZA200408941B (en) | 2007-12-27 |
| RU2004132859A (ru) | 2005-08-27 |
| JP2005522494A (ja) | 2005-07-28 |
| BR0309174A (pt) | 2005-02-09 |
| SE0201125L (sv) | 2003-10-13 |
| US6881398B2 (en) | 2005-04-19 |
| KR20040097351A (ko) | 2004-11-17 |
| SE0201125D0 (sv) | 2002-04-12 |
| MXPA04010003A (es) | 2005-07-01 |
| RU2333014C2 (ru) | 2008-09-10 |
| AU2003222538A1 (en) | 2003-10-27 |
| EP1496967A1 (en) | 2005-01-19 |
| US20030192540A1 (en) | 2003-10-16 |
| CA2482263A1 (en) | 2003-10-23 |
| WO2003086516A1 (en) | 2003-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE524990C2 (sv) | Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver | |
| US7810495B2 (en) | Packaging and delivery of pharmaceuticals and drugs | |
| AU2003230474B2 (en) | De-aggregating and dispersing dry medicament powder into air | |
| US20020144680A1 (en) | Method and device for releasing powder | |
| US8834411B2 (en) | Medical devices for dispensing powders | |
| BG105377A (bg) | Доставяне на аерозолен активен агент с модулиранаустойчивост на потока | |
| EP1496969B1 (en) | Dry powder inhaler | |
| Gangurde et al. | Approaches and devices used in pulmonary drug delivery system: a review | |
| MXPA00012795A (es) | Helio y neon como medios para suministrar farmacos en inhalador. | |
| US20070101991A1 (en) | Optimizing release of dry medicament powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |